1. Provided signed informed consent. <br/ > 2. Previously confirmed diagnosis of SARS-CoV-2 infection (polymerase chain reaction or IgG antibody) between 22 to 100 days prior to the date of randomization with negative test at trial entry screening. <br/ > 3. >3 weeks and < 6 months from symptom onset <br/ > 4. Persistent symptoms defined as either dyspnoea, chest pain, palpitations and/or fatigue. <br/ > 5. Elevated inflammatory markers above normal range (e.g. high sensitivity CRP >2 mg/L or <br/ > neutrophil/lymphocyte ratio >5).

1. Provided signed informed consent. <br/ > 2. Previously confirmed diagnosis of SARS-CoV-2 infection (polymerase chain reaction or IgG antibody) between 22 to 100 days prior to the date of randomization with negative test at trial entry screening. <br/ > 3. >3 weeks and < 6 months from symptom onset <br/ > 4. Persistent symptoms defined as either dyspnoea, chest pain, palpitations and/or fatigue. <br/ > 5. Elevated inflammatory markers above normal range (e.g. high sensitivity CRP >2 mg/L or <br/ > neutrophil/lymphocyte ratio >5).